Amphista Therapeutics Raises $53M in Series B Funding

17 Mar, 2021

Amphista Therapeutics Raises $53M in Series B Funding
Photo by Christine Roy on Unsplash

– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.

Biopharma Biotechnology Europe
Crunchbase icon

Content report

The following text will be sent to our editors: